OMGA - Omega seeks FDA nod to start liver cancer trial of lead drug OTX-2002

Omega Therapeutics (NASDAQ:OMGA) submitted an investigational new drug application to the U.S. Food and Drug Administration (FDA) to get clearance to start a clinical trial of its lead product candidate OTX-2002 for treating a type of liver cancer called hepatocellular carcinoma. "This also marks a milestone regulatory submission for the first epigenomic controller, a new class of programmable mRNA therapeutics enabled by our OMEGA platform," said Omega President and CEO Mahesh Karande. The company plans to begin a phase 1  trial of OTX-2002 in the U.S., following FDA clearance.

For further details see:

Omega seeks FDA nod to start liver cancer trial of lead drug OTX-2002